Varian gains more worldwide sites for RapidArc system

November 15th 2025

How Supportive Care Methods Can Improve Oncology Outcomes

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Experts discussed supportive care and why it should be integrated into standard oncology care.

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD

November 10th 2025

PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors

Experts discussed supportive care and why it should be integrated into standard oncology care.

The Aliya PEF ablation procedure achieved local tumor control in 96% of patients, and was well-tolerated with no delays to SOC therapy.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

The Aliya PEF ablation procedure achieved local tumor control in 96% of patients and was well-tolerated with no delays to SOC therapy.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

November 6th 2025

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Roman Fabbricatore

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

Related Content

November 15th 2025

How Supportive Care Methods Can Improve Oncology Outcomes

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD

November 10th 2025

PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors

Experts discussed supportive care and why it should be integrated into standard oncology care.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

The Aliya PEF ablation procedure achieved local tumor control in 96% of patients and was well-tolerated with no delays to SOC therapy.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

November 6th 2025

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Roman Fabbricatore

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.